PhD Positions Open at Manipal Institute of Regenerative Medicine (MIRM), Bengaluru
The Stem Cell Cytometry and Imaging Lab at the Manipal Institute of Regenerative Medicine (MIRM), is working on understanding morphometry and immuno-heterogeneity-based classification of human mesenchymal stem cells. We are situated in MIRM, MAHE Bengaluru and our Institute is one of the very few niche institutions on Stem Cell Technology and Regenerative Biology.
Currently, there are two positions open, and I am looking for interested PhD candidates for the projects given below.
- Investigating morphometry and immuno-heterogeneity-based classification of stem cells using machine learning-aided tools for applications in biotherapeutics. (Preferable with Bioinformatics/Computational Biology background having programming skills)
- Comprehensive oral mesenchymal stem cell immunoprofiling to understand novel immunotypes showing enhanced osteo- and neurogenesis and their response towards cell senescence. (From any field of Life Sciences, MSc/MTech/MPharm background)
The applications for the MAHE – PhD program 2024-25 Batch 2 open from Oct 11, 2024. Students who do not have their own fellowships can apply through the Manipal Entrance Test (MET) and clear the exam.
Manipal University provides fellowships to PhD students called the TMA Pai fellowships, which students can avail after clearing the exam, followed by an interview with the respective departments.
Candidates
who have qualified NET/UGC-NET assistant professorship exam or GATE/GPAT Exam with cutoff marks applicable for the general category for the academic years 2022, 2023, 2024 are exempted from the PhD Manipal Entrance Test and can apply and join at any time of the year.How to Apply:
Contact: [email protected]
Editor’s Note: PhD Positions Open at Manipal Institute of Regenerative Medicine (MIRM), Bengaluru. Please ensure you are subscribed to the Biotecnika Times Newsletter and our YouTube channel to be notified of the latest industry news. Follow us on social media like Twitter, Telegram, Facebook
